				Patent and Trademark Unice; U.S DEPARTMENT OF COMMERCE	
1	Substitute for form 1449A/PTO		COMPLETE IF KNOWN		
	INFORMATION D	ISCLOSURE	Application Number	10/568,000	
	STATEMENT BY A	DDI ICANT	Filing Date	February 10, 2006	
/ ]	<b>9</b> 5\	APPLICANT	First Named Inventor	Paul J. Coleman .	
	UL 27 2006 (use as many sheets a		Group Art Unit	To be determined	
13/4	(use as many sneeds a	s necessary)	Examiner Name	To be determined	
7	SHEET 1	of 3	Attorney Docket Number	21485YP	
13/4	C TRADENT	-1	Examiner Name		

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Document  Number  Kind Code (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
7Y.C./		6,057,342		Fevig et al.	05/02/2000			
/Y.C./		6,440,686		Sakowicz	08/27/2002			
/Y.C./		3,644,414		Helsey, et al.	02/22/1972			
٠			-	,				
			+					
		·			·			
	<u> </u>							
•								
•								
		·						

			FORE	IGN PATENT	DOCUMENTS	
Examiner	Cite	Foreign Patent Document		Name of Patentee or Applicant	Date of Publication of	
Initials*	No.	Office	e Number	Kind Code (if known)	of Cited Document	Cited Document MM-DD-YYYY
/Y.C./		PCT	WO 93/20099		Yamanouchi Pharm. Co., Ltd.	10/14/1993
IY.C.I		PCT	WO 98/06694		The DuPont Merck Pharm. Co.	02/19/1998
IY.C.I		PCT	WO 03/049527		Merck & Co., Inc.	06/19/2003
IY.C.I		PCT	WO 03/105855		Merck & Co., Inc.	12/24/2003
/Y.C./		РСТ	WO 2004/037171		Merck & Co., Inc.	05/06/2004
/Y.C./	_	PCT	WO 03/106417		Merck & Co., Inc.	12/24/2003
N.C.I		PCT	WO 2005/019206		Merck & Co., Inc.	03/03/2005
/Y.C./		PCT	WO 2005/019205		Merck & Co., Inc.	03/03/2005
N.C.I		EPO	EP 0 418 845		Fujisawa Pharmaceutical Co., Ltd.	08/09/1995
لـــــا			<u> </u>			·

Examiner Signature	/Yong Chu/	Date Considered	12/19/2007

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form, with next communication to applicant.

SEND TO: Computer generated form 1DS Form (IDS Folder), Merck & Co., Inc., -7/12/2005

					Petent and Trademark Office; U.S DEPARTMENT OF COMMERCE
	Substitute for form 1449B/PTO				COMPLETE IF KNOWN
	INFORMATION	DISC	CLOSURE	Application Number	10/568,000
	O STATEMENT BY APPLICANT			Filing Date	February 10, 2006
				First Named Inventor	Paul J. Coleman
,	UL 27 2006		,	Group Art Unit	To be determined
त्रे	(usetls many shee	ts as ne	cessary)	Examiner Name	To be determined
1	Sheet 2	of	3	Attorney Docket Number	21485YP

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
N.C.I		C. Sonesson, et al., J. Org. Chem. 1996, Vol. 61, pg. 4756-4763					
Y.C.I		N. Iwasawa, et al., J. Org. Chem. 1998, Vol. 63, pg. 3164-3165					
N.C.I		N. Iwasawa, et al., J. Org. Chem. 1997, Vol. 62, pg. 1918-1919					
/Y.C./		R. Mison, et al., J. Chem. Research(S), 1989, 126-127					
N.C.I		O. Yebdri, et al., Bulletin De La Societe Chimique de France, 1983, pg. 195-201					
/Y.C./		A. Ranjon, Bulletin De La Societe Chimique de France, 1971, pg. 2068-2072					
N.C.I		M. Bujard, et al., Tetrahedron Letters, Vol. 40, 1999, pg. 8785-8788					
/Y.C./		M. Carpes, et al., Synlett, No. 7, 2000, pg. 1037-1039					
IY.C.I		A. Boukhari, et al., J. Cryst. Spect. Res., Vol. 19, Iss. 3, 1989, pg. 603-621					
N.C.I		C. Cox, et al., Bioorganic & Medicinal Chem Ltrs. Vol. 15, pgs. 2041-2045 (2005)					
/Y.C./		W. Tao, Cell Cycle, Vol. 4(11), pgs. 1495-1499 (2005)					
/Y.C./		K. D. Chu, et al., Proc. Am. Soc. Clin. Oncol., abstract 525, pg. 131 (2003)					
N.C.I		R. Sakowicz, et al., Cancer Research, Vol. 64, pgs. 3276-3280 (2004)					
N.C.I		W. Tao, et al., Cancer Cell, Vol. 8, pgs. 49-59 (2005)					
N.C.I		M. Fraley, et al., Bioorganic & Medicinal Chem Ltrs., Vol. 16, pgs. 1775-1779 (2006)					

Examiner Signature	/Yong Chu/	Date Considered	12/19/2007

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form \* IDS Form\* (IDS Folder), Merck & Co., Idea, -7/12/2005)

	Subst	tute for form 1449B/PTO			COMPLETE IF KNOWN		
	INFORMATION DISCLOSURE			CLOSURE	Application Number	10/568,000	
<u>/</u> C	1 P ACTE	STATEMENT BY APPLICANT			Filing Date	February 10, 2006	
_	7) N	ALEMENI BI	Ar	PLICANI	First Named Inventor	Paul J. Coleman	
JUL	2 7 2006	B)			Group Art Unit	To be determined	
١ ١		yse as many sheet	s as n	necessary)	Examiner Name	To be determined	
& TA	OSIMEEN DE	3	of	3	Attorney Docket Number	21485YP	

NON PATENT LITERATURE DOCUMENTS							
xaminer Cite Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.  No.							
	R. Garbaccio, et al., Bioorganic & Medicinal Chem Ltrs., Vol. 16, pgs. 1780-1783 (2006)						
	C. Cox, et al., Bioorganic & Medicinal Chem Ltrs., Vol. 16, pgs. 3175-3179 (2006)						
	·						
,							
-							
	Cite No.						

Examiner Signature	/Yong Chu/	Date Considered	12/19/2007